XWAR
PTG
Market cap34mUSD
Sep 17, Last price
26.40PLN
1D
-2.58%
1Q
-23.03%
IPO
-57.69%
Name
Poltreg SA
Chart & Performance
P/E
—
P/S
351.76
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.96%
Rev. gr., 5y
-6.89%
Revenues
350k
-74.98%
Net income
-19m
L+38.06%
CFO
-16m
L+20.48%
Profile
Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 350 -74.98% | 1,399 40.04% | 999 -9.10% | ||||
Cost of revenue | 9,236 | 7,163 | 4,627 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (8,886) | (5,764) | (3,628) | ||||
NOPBT Margin | |||||||
Operating Taxes | (3,265) | ||||||
Tax Rate | |||||||
NOPAT | (8,886) | (5,764) | (363) | ||||
Net income | (18,708) 38.06% | (13,551) -1,143.99% | 1,298 -134.35% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | 468 | 393 | 36 | ||||
Long-term debt | 15,470 | 15,995 | 15,753 | ||||
Deferred revenue | 12,498 | ||||||
Other long-term liabilities | 798 | 629 | |||||
Net debt | (30,091) | (49,563) | (74,311) | ||||
| Cash flow | |||||||
Cash from operating activities | (16,005) | (13,284) | (8,602) | ||||
CAPEX | (8,752) | (31,572) | (7,583) | ||||
Cash from investing activities | (8,752) | (31,572) | (5,049) | ||||
Cash from financing activities | 4,461 | 20,771 | (254) | ||||
FCF | (8,094) | (36,890) | (21,085) | ||||
| Balance | |||||||
Cash | 45,655 | 65,951 | 90,036 | ||||
Long term investments | 374 | 64 | |||||
Excess cash | 46,012 | 65,881 | 90,050 | ||||
Stockholders' equity | 69,234 | (25,242) | (11,691) | ||||
Invested Capital | 45,360 | 134,249 | 121,261 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 4,663 | 4,663 | 4,663 | ||||
Price | 36.60 -26.51% | 49.80 8.26% | 46.00 -33.14% | ||||
Market cap | 170,666 -26.51% | 232,217 8.26% | 214,498 -8.71% | ||||
EV | 140,575 | 182,654 | 140,187 | ||||
EBITDA | (4,880) | (4,713) | (2,805) | ||||
EV/EBITDA | |||||||
Interest | 837 | 356 | 284 | ||||
Interest/NOPBT | |||||||